Access to care of patients with chronic hepatitis C virus infection in a university hospital: Is opioid dependence a limiting condition?

Drug and Alcohol Dependence

Volumn 104, Issue 1-2, 2009, Pages 78-83

  Perut, Valerie ^a   Labalette, Celine ^a   Sogni, Philippe ^b   Ferrand, Isabelle ^a   Salmon Céron, Dominique ^b   Vidal Trecan, Gwenaelle ^a,b  

^a Institut Cochin   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Hepatitis C; Opioid related disorders; Patient care management

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; FEMALE; FRANCE; GENOTYPE; HEALTH CARE ACCESS; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; UNEMPLOYMENT; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HOSPITALS, UNIVERSITY; HUMANS; LIVER; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PARIS; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 67749085904     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2009.04.002     Document Type: Article

References (32)

1. Agostini H., Castera L., Melin P., Cattan L., and Roudot-Thoraval F. HEPACOM: multicenter, observational prospective study of outcome and monitoring of HCV positive antiviral-naive patients managed in the French health care system. Gastroenterol. Clin. Biol. 31 (2007) 1074-1080
2. Anonymous, 1997. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology, 26, 2S-10S.
3. Anonymous, 1999. International consensus conference on hepatitis C. Conclusions. The European Association for the Study of the Liver (EASL) Paris, February 26-28. Gastroenterol. Clin. Biol., 23, 730-735.
4. Bedossa P., Poynard T., and The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24 (1996) 289-293
5. Butt A.A., Wagener M., Shakil A.O., and Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J. Viral. Hepat. 12 (2005) 81-85
6. Cacoub P., Rosenthal E., Halfon P., Sene D., Perronne C., and Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J. Viral. Hepat. 13 (2006) 678-682
7. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., and Benzekri A. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292 (2004) 2839-2848
8. Carrieri M.P., Moatti J.P., Vlahov D., Obadia Y., Reynaud-Maurupt C., Chesney M., and MANIF 2000 Study Group. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. J. Epidemiol. Community Health 53 (1999) 4-8
9. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., Darriet M., Couzigou P., and De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005) 343-350
10. Cournot M., Glibert A., Castel F., Druart F., Imani K., Lauwers-Cances V., and Morin T. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol. Clin. Biol. 28 (2004) 533-539
11. Frere T., Verneau A., Besson I., de Bayser L., Dupuychaffray J.P., Kitmacher P., Silvain C., and Beauchant M. Treatment of hepatitis C virus infection in the Poitou-Charentes region. Gastroenterol. Clin. Biol. 23 (1999) 887-891
12. Goegebeur G., Benhamiche A.M., Minello A., Rassiat E., Clinard F., Milan C., Faivre J., Hillon P., and The Research Group of the REBOHC. The characteristics of patients with hepatitis C virus antibodies followed in specialized university hospital units are different from those of patients in the general population. Gastroenterol. Clin. Biol. 24 (2000) 1042-1046
13. Guyader D., Lefeuvre C., Jacquelinet S., Prat M., Baudouard Y., Turlin B., Andre P., Mendler M.H., Sapey T., Boucher E., Moirand R., Messner M., Colimon R., Brissot P., and Deugnier Y. Epidemiology of hepatitis C virus infection in 1,304 HCV positive patients: variations according to the origin of transmission and year of diagnosis. Gastroenterol. Clin. Biol. 22 (1998) 375-380
14. Hatem C., Minello A., Bresson-Hadni S., Jooste V., Evrard P., Obert B., Lepage C., Bonithon-Kopp C., Faivre J., Monnet E., Miguet J.P., and Hillon P. Is the management of hepatitis C patients appropriate? A population-based study. Aliment. Pharmacol. Ther. 21 (2005) 1007-1015
15. Hu D.J., Byers Jr. R., Fleming P.L., and Ward J.W. Characteristics of persons with late AIDS diagnosis in the United States. Am. J. Prev. Med. 11 (1995) 114-119
16. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
17. Meffre C., Le Strat Y., Delarocque-Astagneau E., Meyer J.F., Coste D., et al. Prevalence of hepatitis C in France, 2003-2004. J. Hepatol. 44 S2 (2006) S201
18. Rai R., Wilson L.E., Astemborski J., Anania F., Torbenson M., Spoler C., Vlahov D., Strathdee S.A., Boitnott J., Nelson K.E., and Thomas D.L. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 35 (2002) 1247-1255
19. Rey D., Carrieri M.P., Spire B., Loubiere S., Dellamonica P., Gallais H., Cassuto G.P., Gastaut J.A., and Obadia Y. Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment. J. Urban Health 81 (2004) 48-57
20. Robaeys G., and Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastroenterol. Belg. 68 (2005) 55-67
21. Robaeys G., Van Vlierberghe H., Mathei C., Van Ranst M., Bruckers L., and Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur. J. Gastroenterol. Hepatol. 18 (2006) 159-166
22. Roudot-Thoraval F., Bastie A., Pawlotsky J.M., Dhumeaux D., and The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 26 (1997) 485-490
23. Roy K., Hay G., Andragetti R., Taylor A., Goldberg D., and Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol. Infect. 129 (2002) 577-585
24. Seeff L.B., and Hoofnagle J.H. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 36 (2002) S1-S2
25. Sheerin I.G., Green F.T., and Sellman J.D. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand. Drug Alcohol Rev. 22 (2003) 159-167
26. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5 (2005) 558-567
27. Stoove M.A., Gifford S.M., and Dore G.J. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend. 77 (2005) 81-86
28. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzales-Garcia J., Lazzarin A., Carosi G., Sasadeusz J., Katlama C., Montaner J., Sette, Passe S., De Pamphilis J., Duff F., Schrenk U.M., Dieterich D.T., and APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 351 5 (2004) 438-450
29. Van Thiel D.H., Anantharaju A., and Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am. J. Gastroenterol. 98 (2003) 2281-2288
30. Williams I. Epidemiology of hepatitis C in the United States. Am. J. Med. 107 (1999) 2S-9S
31. Zehnter E. Treatment of chronic hepatitis C with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) in patients with HIV coinfection in the real-life setting in Germany. AASLD meeting. Boston (2007)
32. Ziol M., Handra-Luca A., Kettaneh A., Christidis C., Mal F., Kazemi F., de L.V., Marcellin P., Dhumeaux D., Trinchet J.C., and Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 (2005) 48-54